Autres langues CSPC Pharmaceutical Group Limited

Actions

1093

HK1093012172

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:27 30/09/2026			Varia. 5j.	Varia. 1 janv.
10,07 ^HKD	+6,28 %		+3,71 %	+19,45 %

14:20	Les grands laboratoires pharmaceutiques se tournent vers la Chine pour leurs accords de licence	RE
29/09	Le secteur pharmaceutique mise davantage sur l’IA pour réduire les coûts et les délais	RE

Autres langues

16:46	Weight-loss drug developers line up to tap lucrative market as competition heats up
14:20	Major drugmakers turn to China for licensing deals
29/09	Pharma sector doubles down on AI to slash costs, timelines
29/09	CSPC Pharma Gets US FDA Approval to Start Herpes Zoster Vaccine Trial
29/09	CSPC Pharma Begins Phase 1b Trial of Weight Management Drug in China
28/09	CSPC Pharma Gets China Nod for Tumor Drug Trial
24/09	CSPC Pharmaceutical Group Limited Initiates Phase III Clinical Trial Of Docetaxel For Injection (Albumin-Bound) For Treatment Of Advanced Breast Cancer In China
24/09	CSPC Pharmaceutical Group Limited Announces Phase III Clinical Trial Of Becotatug In Combination With Osimertinib Achieves Positive Topline Results
24/09	CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results
24/09	CSPC Pharm Begins Phase III Breast Cancer Drug Trial
21/09	Pharma sector doubles down on AI to slash costs, timelines
21/09	US Considers Rules Allowing American Investment in Chinese Drugs
16/09	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2069 Injection For Treatment Of Type 2 Diabetes Mellitus In Adult Patients At First Centre In China
16/09	Pharma sector doubles down on AI to slash costs, timelines
16/09	CSPC Pharma Begins Diabetes Drug Trial in China
15/09	CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Drug
15/09	CSPC Pharmaceutical says SYS6010 granted breakthrough therapy designation by NMPA
15/09	CSPC Pharmaceutical Group Limited Receives Breakthrough Therapy Designation For SYS6010 By NMPA In China For Treatment Of Actionable Genomic Alteration-Negative Non-Squamous Non-Small Cell Lung Cancer
14/09	CSPC Pharmaceutical Group Limited Presents Phase I/II Clinical Trial Data Of SYS6010 In Combination With Enlonstobart For Treatment Of Advanced NSCLC At 2026 World Conference On Lung Cancer
09/09	CSPC Pharma's SYH9087 Injection Gets China Nod for Parkinson's Disease Trial
09/09	CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug
09/09	CSPC Pharmaceutical Group Limited Announces Dopamine Receptor Agonist Rotigotine Long-Acting Injection (SYH9087 Injection)
09/09	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For Goserelin Sustained-Release Injection (SYH9102 Injection)
08/09	CSPC Pharmaceutical Group Limited SYH2083 Eye Drops Obtain Clinical Trial Approval In China
08/09	CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials